Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4

BACKGROUND: Antibodies and derivative drugs targeting immune checkpoints have been approved for the treatment of several malignancies, but there are fewer responses in patients with pancreatic cancer. Here, we designed a nanobody molecule with bi-targeting on PD-L1 and CXCR4, as both targets are ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Shuai, Xu, Shuyi, Li, Liangzhu, Li, Yaxian, Zhao, Meiqi, Chen, Junsheng, Zhu, Shunying, Xie, Yueqing, Jiang, Hua, Zhu, Jianwei, Wu, Mingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594910/
https://www.ncbi.nlm.nih.gov/pubmed/36284271
http://dx.doi.org/10.1186/s12885-022-10165-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594910/
https://www.ncbi.nlm.nih.gov/pubmed/36284271
http://dx.doi.org/10.1186/s12885-022-10165-7

Ejemplares similares